Among the CSC-targeting strategies explored in lung cancer to date, genetic knockdown or pharmacological inhibition of ALDH1 has been shown to attenuate the proliferative and migratory capabilities of NSCLC cells [88]. The gene discussed is ALDH1A1; the disease is lung cancer.